Skip to main content

Table 1 PARP inhibitors under clinical investigation in malignant disease

From: Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?

Agent (year entered clinical research) Manufacturer Single/combination therapy Oral/intravenous Clinical indication(s) Status
AG014699, PF0367338 (2003) Pfizer (New York, NY, USA) Single agent; multiple combinations Intravenous and oral Solid tumours; melanoma; BRCA germline Phase I and II melanoma studies complete. Phase II BRCA studies open
KU59436, AZD2281, olaparib (2005) AstraZeneca/KuDOS (London, UK) Single agent; multiple combinations Oral Various, including BRCA germline Phase I complete. Numerous phase II studies ongoing
ABT-888, veliparib (2006) Abbott Laboratories (North Chicago, IL, USA) Multiple combinations Oral Solid tumours; melanoma; lymphoid malignancies Phase 0/I completed in some indications Numerous phase II studies ongoing
BSI-201, SAR 240550 iniparib (2006) BiPar (South San Francisco, CA, USA; Sanofi Aventis) Combination with gemcitabine and carboplatin; temozolomide Intravenous TNBC; lung cancer; glioma Phase II studies completed. Phase III study in TNBC recruiting. Phase II study in lung near completion
INO-1001 (2005/2006) Inotek/Genentech (Lexington, MA, USA) Single agent; combination with temozolomide Intravenous Melanoma; malignant glioma Phase Ib in melanoma completed
MK4827 (2008) Merck Sharp Dohme (Hoddesdon, UK) Single agent; combination with chemotherapy Oral Solid tumours; BRCA- related ovarian cancer Phase I ongoing
CEP-9722 (2009) Cephalon (Frazer, PA, USA) Single agent; combination with temozolomide Oral Solid tumours Phase I ongoing
GPI 21016 (2010) MGI Pharma (Bloomington, MN, USA) Combination with temozolomide Oral Solid tumours Phase I ongoing
E7016 (2010) MGI Pharma (Bloomington, MN, USA), Eisai (Baltimore, MD, USA) Combination with temozolomide Oral Solid tumours Phase I ongoing
LT673 (2011) Lead Therapeutics/Biomarin (Novato, CA, USA) Single agent and combination planned Oral Solid tumours Phase I planned
  1. PARP, poly(ADP-ribose) polymerase; TNBC, triple-negative breast cancer.